Afuco™ Anti-CD33 ADCC Therapeutic Antibody (Vadastuximab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD33. Vadastuximab is a chimeric (mouse/human) monoclonal antibody that can be potentially used in the treatment of Acute myeloid leukemia (AML).
Supplier Creative Biolabs
Product # AFC-TAB-471CQ
Pricing Inquiry
Host Human
Target CD33
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, IHC, FC, IP, IF, FuncS
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback